ArticleBioengineering & translational medicine2026
Stealth polymer coatings of reactive oxygen species scavenging nanoparticles for immune response mitigation.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early career innovators shaping the future of bioengineering and translational medicine.Bioengineering & translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated levels of reactive oxygen species play an integral role in chronic inflammation. Current treatments for chronic inflammation often ignore reactive oxygen species and instead focus on symptom control or immunosuppression. However, by controlling reactive oxygen species in inflammatory environments, cyclic inflammation can be reduced. Combining reactive oxygen species scavenging delivery systems with stealth coatings can help avoid the innate immune system and enable targeted delivery to sites of inflammation without causing further oxidative stress. For this purpose, poly(propylene sulfide) nanoparticles were synthesized utilizing two different surfactants, Pluronic F-127 and sucrose monolaurate, adding stealth properties to the coatings of the reactive oxygen species scavenging nanoparticles. Characterization of the nanoparticles demonstrated the surfactant coatings did not affect the scavenging abilities nor the cytocompatibility of the materials. Degradation of the nanoparticles related to the sulfide groups and disulfide bond interactions with reactive oxygen species was also analyzed. Moreover, proinflammatory cytokine secretion from macrophages exposed to the nanoparticles was investigated to determine immune response evasion. Results obtained showed little to no activation of macrophages exposed to nanoparticle formulations in regard to MCP-1 cytokine release. However, there is room for improvement using glycerol-based coatings with regard to protecting cells from reactive oxygen species exposure and reducing macrophage activation in relation to IL-6 and TNF-alpha. Overall, the nanoparticles investigated have the capabilities to improve inflammatory disease treatments by not only targeting delivery of therapeutics to the site of inflammation, but also avoiding excess immune response recruitment due to incorporation of stealth coatings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.